20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Go back to 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
(NASDAQ: AIDX) Delayed: 0.27 --0 (-0%)
Previous Close $0.27    52 Week High $ 
Open $0.27    52 Week Low $ 
Day High $0.28    P/E N/A 
Day Low $0.27    EPS $ 
Volume 18,999       

(NASDAQ: AIDX) Delayed: 0.27 --0 (-0%)
Previous Close $0.27    52 Week High $ 
Open $0.27    52 Week Low $ 
Day High $0.28    P/E N/A 
Day Low $0.27    EPS $ 
Volume 18,999